Transforming biomarker development with exceptional responders Journal Article
| Authors: | Jonsson, P.; Taylor, B. S. |
| Article Title: | Transforming biomarker development with exceptional responders |
| Abstract: | Curative therapy for cancer patients with advanced-stage disease remains elusive. While rare outlier responses to anticancer therapies exist, barriers limit our understanding of the molecular and genetic basis of such profound, life-altering responses. Here, we describe how phenotype-to-genotype studies are elucidating the molecular underpinnings of outlier responses and informing strategies to extend such unprecedented sensitivity to broader molecularly defined patient populations. © 2017 Elsevier Inc. |
| Keywords: | signal transduction; cancer chemotherapy; treatment response; gene mutation; sorafenib; erlotinib; drug efficacy; nonhuman; drug targeting; molecular genetics; cancer immunotherapy; chemosensitivity; tumor marker; cancer therapy; cancer resistance; drug response; genomics; short survey; dna damage response; trastuzumab; epidermal growth factor receptor kinase inhibitor; personalized medicine; sequencing; genotype phenotype correlation; clinical outcome; selumetinib; human; priority journal; precision medicine; molecular oncology; exceptional response |
| Journal Title: | Trends in Cancer |
| Volume: | 4 |
| Issue: | 1 |
| ISSN: | 2405-8025 |
| Publisher: | Cell Press |
| Date Published: | 2018-01-01 |
| Start Page: | 3 |
| End Page: | 6 |
| Language: | English |
| DOI: | 10.1016/j.trecan.2017.11.004 |
| PROVIDER: | scopus |
| PMCID: | PMC5806204 |
| PUBMED: | 29413420 |
| DOI/URL: | |
| Notes: | Short Survey -- Export Date: 1 March 2018 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work